A Multi-Center, Randomized, Double-Blind, Placebo-controlled Study of Adalimumab in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis.
Phase of Trial: Phase II/III
Latest Information Update: 20 May 2016
At a glance
- Drugs Adalimumab (Primary)
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie
- 01 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Jan 2011 Additional lead trial investigator (Kazuko Kobayashi) identified as reported by ClinicalTrials.gov.
- 04 Jan 2011 Trial phase changed from phase II/III to phase III as reported by ClinicalTrials.gov.